Skip to content
Medical Health Aged Care, National News Current Affairs

Alcohol remains leading cause for drug treatment in Australia

FARE and Turning Point 4 mins read
  • Media:

The number of Australians receiving treatment for alcohol continues to eclipse all other drugs, highlighting the urgent need to address the predatory marketing practices of alcohol companies.

New data released today by the Australian Institute of Health and Welfare (AIHW) shows alcohol was the principal drug of concern for people seeking treatment in 2023-24, accounting for two in five (42 per cent) of the 219,277 episodes of treatment – compared to amphetamines (26 per cent), cannabis (16 per cent) and heroin (4 per cent).

Principal drugs of concern are defined by the AIHW as, ‘the main substance that the client stated led them to seek treatment from an alcohol and drug treatment agency.’

While 131,892 people accessed treatment, a slight increase from 131,500 in the previous year, there’s still far too many people unable to get the support they need. Recent research estimates that between 207,000[i] and 500,000[ii] Australians who need help for addiction cannot access it.

Foundation for Alcohol Research and Education (FARE) Director of Policy and Research, Dr Catherine Earl said the report shows that more needs to be done to better regulate alcohol companies that relentlessly target people with advertising.

“We know that many of the people in our communities who are seeking treatment for alcohol use are at the same time often aggressively targeted by alcohol companies through online ads on social media, and other online platforms.

“Alcohol companies are collecting more data on people than ever before, so when every phone is both a billboard and a bottle shop, it’s almost impossible for people to escape these ads when they are trying to cut back.”

Professor Dan Lubman, Executive Clinical Director of Turning Point and Director of the Monash Addiction Research Centre, said the new data highlights a large gap between the demand for and availability of support, and the impact of stigma and inadequate health promotion.

"Last year, around 400 more Australians accessed alcohol and drug treatment compared to the previous year. While it's encouraging to see more people getting help, it's concerning that the increase isn't larger,” said Professor Lubman.

“While we know about half a million Australians need support for alcohol or drug issues, fewer than 132,000 received it. This gap highlights a significant shortfall in our healthcare system.

“The recent federal Parliamentary Inquiry into the health impacts of alcohol and drug use recommended that the 48th Parliament complete a full report into the issue. It’s vital that this goes ahead.

“These numbers aren't just statistics. They represent real people - friends, family, coworkers and neighbours. It's critical that all Australians can access the treatment and support they need to live healthy and meaningful lives.”

Dr Earl added that bold action from governments is needed to ensure community safeguards are adequate for our digital age and are helping protect Australians who experience the greatest impacts from alcohol harm.

“There are common sense measures that can make a real difference now, like changes to the Privacy Act, ensuring people’s data isn’t collected to market addictive products to those already struggling with alcohol.

“State and territory governments also have a role to play, and should update their liquor laws to ensure stronger protections around the delivery of alcohol, including a ban on late night home delivery and a two-hour safety pause between an order being placed and delivered.

“We need to do more to prevent this harm, we need the Federal and State Governments to implement the common sense protections that will put the health and wellbeing of families and communities ahead of the interests of the alcohol industry.”

The new data showing alcohol is the most common principal drug of concern is contained in the AIHW’s report: Alcohol and other drug treatment services in Australia: Early insights.

-ENDS-

Media outlets are requested to promote help-seeking information when reporting on alcohol and other drugs, in line with the
Mindframe National Guidelines. Suggested wording relating this this media story: If you or someone you know needs support, please call Lifeline 13 11 14, the National 24/7 Alcohol and Other Drugs Hotline 1800 250 015 or 1800RESPECT 1800 737 732.

Available for interview:

  • FARE Policy and Research Director, Dr Catherine Earl
  • Turning Point CEO, Professor Dan Lubman


[i] Ritter A, O'Reilly K. Unmet treatment need: The size of the gap for alcohol and other drugs in Australia. Drug Alcohol Rev. 2025; 44(3): 772–782.

[ii] Ritter A, Chalmers J, Gomez M. Measuring Unmet Demand for Alcohol and Other Drug Treatment: The Application of an Australian Population-Based Planning Model. J Stud Alcohol Drugs Suppl. 2019 Jan;Sup 18(18):42-50.


About us:

The Foundation for Alcohol Research and Education (FARE) is a not-for-profit organisation with a vision for an Australia free from alcohol harms – where communities are healthy and well and where laws, policies and programs are fair, equitable and just. Working with local communities, people with lived experience of alcohol harm, values-aligned organisations, health professionals, researchers and governments across the nation, we are improving the health and wellbeing of everyone in Australia. To learn more about us and our work visit www.fare.org.au

Turning Point is a national treatment, research and education centre that provides leadership in the alcohol and other drug, gambling and mental health sectors. Combining innovative clinical and population health research and expert policy advice with service innovation, surveillance, system enhancements, capacity building and specialist support, Turning Point empowers people, communities, services and governments to respond to current and emerging alcohol, other drug, and gambling harms. Turning Point is part of Eastern Health and is affiliated with Monash University.


Contact details:

FARE: Kristy Tass | media@fare.org.au | 0429 291 120
Turning Point: Jack Bannister | Jack.Banister@easternhealth.org.au | 0423 320 743

Media

Attachments

Media-Release_Alcohol-remains-leading-cause-for-drug-treatment-in-Australia_Apr2025.pdf

Download media

More from this category

  • Medical Health Aged Care
  • 18/04/2025
  • 07:00
Monash University

Experts warn of increased alcohol harms over the Easter long weekend

Heavy alcohol consumption is usually associated with the summer months, not with Easter. But new analysis of Victorian ambulance data shows that there are regularly more than 500 alcohol-related attendances over the Easter long weekend. This heightened level of alcohol harm means the upcoming four-day weekend is the equivalent of four successive Saturday nights, and Victorians should consider their alcohol consumption and plan to stay safe as they prepare for Easter. The analysis reaffirms the findings of other projects led by the National Ambulance Surveillance System (NASS) at Turning Point and Monash University. VicHealth-funded research into the 2022 calendar year…

  • Contains:
  • Medical Health Aged Care
  • 17/04/2025
  • 23:26
Avania

Avania Strengthens Leadership Team With Pivotal Executive Appointments

BILTHOVEN, Netherlands & BOSTON–BUSINESS WIRE– Avania — the leading global MedTech advisory and clinical development partner — today announced the appointments of Jasmine Saba…

  • Contains:
  • Medical Health Aged Care
  • 17/04/2025
  • 22:11
Tilray Brands, Inc.

Tilray Medical Introduces Cannabis Edibles in Australia

Tilray Medical Expands Offerings with Good Supply Brand Medical Cannabis Pastilles for Australian PatientsSYDNEY, April 17, 2025 (GLOBE NEWSWIRE) -- Tilray Medical (“Tilray”), a division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), a global company in medicinal cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, has announced the availability of its medical cannabis edibles, Good Supply Pastilles, to patients in Australia. This launch marks Tilray Medical's first medical cannabis edible offering in the country, providing patients with a sugar-free and vegan-friendly treatment option.Denise Faltischek, Chief Strategy Officer and Head of…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.